| Online-Ressource |
Verfasst von: | Brückl, Wolfgang M. [VerfasserIn]  |
| Reck, Martin [VerfasserIn]  |
| Rittmeyer, Achim [VerfasserIn]  |
| Kollmeier, Jens [VerfasserIn]  |
| Wesseler, Claas [VerfasserIn]  |
| Wiest, Gunther H. [VerfasserIn]  |
| Christopoulos, Petros [VerfasserIn]  |
| Tufman, Amanda [VerfasserIn]  |
| Hoffknecht, Petra [VerfasserIn]  |
| Ulm, Bernhard [VerfasserIn]  |
| Reich, Fabian [VerfasserIn]  |
| Ficker, Joachim H. [VerfasserIn]  |
| Laack, Eckart [VerfasserIn]  |
Titel: | Efficacy of docetaxel plus ramucirumab as palliative third-line therapy following second-line immune-checkpoint-inhibitor treatment in patients with non-small-cell lung cancer stage IV |
Titelzusatz: | $hWolfgang M. Brueckl, Martin Reck, Achim Rittmeyer, Jens Kollmeier, Claas Wesseler, Gunther H. Wiest, Petros Christopoulos, Amanda Tufman, Petra Hoffknecht, Bernhard Ulm, Fabian Reich, Joachim H. Ficker and Eckart Laack |
E-Jahr: | 2020 |
Jahr: | August 19, 2020 |
Umfang: | 9 S. |
Fussnoten: | Gesehen am 26.10.2020 |
Titel Quelle: | Enthalten in: Clinical medicine insights. Oncology |
Ort Quelle: | Thousand Oaks, CA : Sage Publications, 2010 |
Jahr Quelle: | 2020 |
Band/Heft Quelle: | 14(2020), Seite 1-9 |
ISSN Quelle: | 1179-5549 |
Abstract: | Background: Antiangiogenic agents have been shown to stimulate the immune system and cause synergistic effects with chemotherapy. Effects might be even stronger after immune-checkpoint-inhibitor (ICI) therapy. The purpose of this analysis was to evaluate the efficacy of ramucirumab plus docetaxel (R + D) as third-line treatment after failure of a first-line platinum-based chemotherapy and a second-line ICI treatment in patients with non-small-cell lung cancer (NSCLC) stage IV. Methods: Retrospective data were collected from 9 German thoracic oncology centers. Only patients who had received at least 1 cycle of third-line R + D were included. The numbers of cycles, objective response rate (ORR), progression-free survival (PFS), and overall survival (OS) were investigated. Results: Sixty-seven patients met the criteria for inclusion. Third-line treatment with R + D achieved an ORR of 36% and a disease control rate (DCR) of 69%. Median PFS for third-line therapy was 6.8 months with a duration of response (DOR) of 10.2 months. A median OS of 29 months was observed from the start of first-line therapy with a median OS of 11.0 months from the start of third-line treatment. No unexpected toxicities occurred. Conclusion: R + D is a highly effective and safe third-line treatment after failure of second-line programmed cell death protein 1/programmed cell death-ligand 1 (PD1/PD-L1)-derived ICI therapy irrespective of NSCLC histology. As there may be synergistic effects of second- and third-line treatments, this sequence is a very suitable option for patients not treated with first-line ICI. In addition, R + D should continue to be investigated as a second-line treatment option after failure of chemotherapy plus ICI in the palliative first–line treatment. |
DOI: | doi:10.1177/1179554920951358 |
URL: | Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.
Volltext: https://doi.org/10.1177/1179554920951358 |
| Volltext: https://journals.sagepub.com/doi/10.1177/1179554920951358 |
| DOI: https://doi.org/10.1177/1179554920951358 |
Datenträger: | Online-Ressource |
Sprache: | eng |
K10plus-PPN: | 1736561502 |
Verknüpfungen: | → Zeitschrift |
Efficacy of docetaxel plus ramucirumab as palliative third-line therapy following second-line immune-checkpoint-inhibitor treatment in patients with non-small-cell lung cancer stage IV / Brückl, Wolfgang M. [VerfasserIn]; August 19, 2020 (Online-Ressource)